OA
REGN icon

Oxbow Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Oxbow Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.12M Buy
5,334
+7
+0.1% +$5.36K 0.35% 77
2025
Q4 		$4.11M Buy
5,327
+80
+2% +$54.3K 0.36% 76
2025
Q3 		$2.95M Buy
+5,247
New +$2.97M 0.27% 90
2025
Q2 		– Sell
-3,653
Closed -$2.32M – 217
2025
Q1 		$2.32M Buy
+3,653
New +$2.51M 0.24% 81

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Oxbow Advisors's REGN Position: Q1 2026 in Review

Oxbow Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 0.13% in Q1 2026, buying an estimated $5.36K and bringing the position to 5,334 shares worth $4.12M. The position accounts for 0.35% of the portfolio, ranked #77.

Oxbow Advisors first reported a position in REGN in Q1 2025 and has held it in 4 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Oxbow Advisors held 5,334 shares of Regeneron Pharmaceuticals worth $4.12M as of Q1 2026.
  • Oxbow Advisors bought 7 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $5.36K.
  • Regeneron Pharmaceuticals made up 0.35% of Oxbow Advisors's portfolio in Q1 2026, its #77 holding.
  • Oxbow Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Oxbow Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.